Panbela Therapeutics, Inc. has filed a prospectus supplement on October 28, 2024, to update and supplement information related to the issuance of various securities as detailed in their June 16, 2023, prospectus. The supplement includes the issuance of 2,270,000 shares of common stock, Class A and Class B Common Warrants to purchase up to 2,270,000 shares each, Pre-Funded Warrants to purchase up to 2,270,000 shares, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' and was last reported at $0.34 per share. Additionally, Panbela Therapeutics entered into a Note Purchase Agreement with Nant Capital, LLC on October 22, 2024, issuing a Senior Convertible Promissory Tranche A Note for $2,850,000 and agreeing to issue a Tranche...Show More

Panbela Therapeutics, Inc. has filed a prospectus supplement on October 28, 2024, to update and supplement information related to the issuance of various securities as detailed in their June 16, 2023, prospectus. The supplement includes the issuance of 2,270,000 shares of common stock, Class A and Class B Common Warrants to purchase up to 2,270,000 shares each, Pre-Funded Warrants to purchase up to 2,270,000 shares, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' and was last reported at $0.34 per share. Additionally, Panbela Therapeutics entered into a Note Purchase Agreement with Nant Capital, LLC on October 22, 2024, issuing a Senior Convertible Promissory Tranche A Note for $2,850,000 and agreeing to issue a Tranche B Note for $9,150,000 by November 15, 2024. The proceeds will be used for general corporate purposes and to repay existing debts. The notes are convertible into common stock at $0.37 per share, subject to a 33.33% beneficial ownership cap for the investor. The company's subsidiaries, Cancer Prevention Pharmaceuticals, Inc. and Panbela Research, Inc., have guaranteed the company's obligations under the agreement.